-- Robert Preidt
WEDNESDAY, Feb. 19, 2014 (HealthDay News) -- Just a few years
after its introduction, a human papillomavirus (HPV) vaccine has
reduced the risk of precancerous cervical lesions among young women
in Denmark, a new study finds.
According to the U.S. National Cancer Institute, infections with
HPV "cause virtually all cervical cancers." Two HPV vaccines,
Gardasil and Cervarix, have been approved for use in the United
States and are currently recommended for use in girls and boys
starting at ages 11 and 12.
While it's too soon to say for sure that HPV vaccination can
lower cervical cancer risk, the Danish study offers more evidence
that it might.
The study, led by Birgitte Baldur-Felskov of the Danish Cancer
Society Research Center in Copenhagen, examined the impact of the
Gardasil HPV vaccine, which protects against four strains of the
virus known to raise the risk for cervical cancer.
The vaccine was approved in Denmark in 2006 and then became part
of the free general childhood vaccination program for girls. The
vaccine is also available for a fee to girls and women and to boys
and men not covered by the program.
In the study, Baldur-Felskov and colleagues looked at HPV
vaccination data from 2006 to 2012 for all girls and women born in
Denmark between 1989 and 1999, as well as how many of them were
diagnosed with cervical lesions.
Those who received HPV vaccination had a much lower risk for
these precancerous lesions compared to those who weren't
vaccinated, the researchers said.
The investigators also found no cervical lesions among girls
born between 1997 and 1999, according to the study which was
published Feb. 19 in the
Journal of the National Cancer Institute.
"In conclusion, our results show that vaccination with the [four-strain] HPV vaccine is already effective in reducing the risk for cervical precursor lesions at population level among young women in Denmark," the researchers concluded.
Two experts in the United States welcomed the findings.
"Studies such as this one continue to support the effectiveness of the HPV vaccine in preventing cervical lesions which lead to cervical cancer," said Dr. Jennifer Wu, an obstetrician/gynecologist at Lenox Hill Hospital in New York City.
Dr. Eva Chalas, chief of gynecologic oncology at
Winthrop-University Hospital in Mineola, N.Y., agreed. She called
the new research "yet another study which underscores the value of
HPV vaccination of young women in preventing precancerous lesions
of the cervix."
However, uptake of the HPV vaccine has been low in the United
States, she noted. "The overwhelming majority of women are still
not getting vaccinated in this country," Chalas said. "In addition,
less than 10 percent of the boys are getting vaccinated. Since the
virus is sexually transmitted, protection of women and men must be
strongly encouraged, and is of greatest benefit before they become
The U.S. National Cancer Institute has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.